NovoCure (FRA:038) Price-to-Operating-Cash-Flow

: (As of Today)

View and export this data going back to 2015. Start your Free Trial

As of today (2024-04-19), NovoCure's share price is €11.175. NovoCure's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.64. Hence, NovoCure's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for NovoCure's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 11 years, NovoCure's highest Price-to-Operating-Cash-Flow Ratio was 554.65. The lowest was 71.86. And the median was 197.32.

FRA:038's Price-to-Operating-Cash-Flow is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 20.36
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

NovoCure's Cash Flow from Operations per share for the three months ended in Dec. 2023 was €-0.13. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.64.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of NovoCure was -334.40% per year.

During the past 11 years, NovoCure's highest 3-Year average Operating Cash Flow per Share Growth Rate was 81.70% per year. The lowest was -19.80% per year. And the median was 15.50% per year.

NovoCure Price-to-Operating-Cash-Flow Historical Data

The historical data trend for NovoCure's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

307.55

189.95

93.85

249.49

NovoCure Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow																249.49	349.65	-	-	-

Competitive Comparison

For the Medical Devices subindustry, NovoCure's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NovoCure Price-to-Operating-Cash-Flow Distribution

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where NovoCure's Price-to-Operating-Cash-Flow falls into.

NovoCure Price-to-Operating-Cash-Flow Calculation

NovoCure's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	11.175	/	-0.639
	=

NovoCure's Share Price of today is €11.175.
NovoCure's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.64.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

NovoCure Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of NovoCure's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

NovoCure (FRA:038) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (FRA:038) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

NVCR:USA 038:Germany

Address

Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF

Website

https://www.novocure.com

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. Products are comprised of two main components: electric field generator and arrays and related accessories. NovoCure derives its major revenues in the United States.

NovoCure (FRA:038) Headlines

No Headlines